PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Vecchio, F.* ; Carré, A.* ; Korenkov, D.* ; Zhou, Z.* ; Apaolaza Gallegos, S.P. ; Tuomela, S.* ; Burgos-Morales, O.* ; Snowhite, I.* ; Perez-Hernandez, J.* ; Brandao, B.* ; Afonso, G.* ; Halliez, C.* ; Kaddis, J.* ; Kent, S.C.* ; Nakayama, M.* ; Richardson, S.J.* ; Vinh, J.* ; Verdier, Y.* ; Laiho, J.* ; Scharfmann, R.* ; Solimena, M. ; Marinicova, Z. ; Bismuth, E.* ; Lucidarme, N.* ; Sánchez, J.* ; Bustamante, C.* ; Gomez, P.* ; Buus, S.* ; You, S.H.* ; Pugliese, A.* ; Hyoty, H.* ; Rodriguez-Calvo, T. ; Flodstrom-Tullberg, M.* ; Mallone, R.*

Coxsackievirus infection induces direct pancreatic β cell killing but poor antiviral CD8+ T cell responses.

Sci. Adv. 10:eadl1122 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β cell autoimmunity and type 1 diabetes. We investigated how CVB affects human β cells and anti-CVB T cell responses. β cells were efficiently infected by CVB in vitro, down-regulated human leukocyte antigen (HLA) class I, and presented few, selected HLA-bound viral peptides. Circulating CD8+ T cells from CVB-seropositive individuals recognized a fraction of these peptides; only another subfraction was targeted by effector/memory T cells that expressed exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with β cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Our in vitro and ex vivo data highlight limited CD8+ T cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8+ T cells recognizing structural and nonstructural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.
Impact Factor
Scopus SNIP
Altmetric
11.700
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Recent-onset; Type-1; Virus; Risk; Identification; Replication; B1; B3
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 2375-2548
e-ISSN 2375-2548
Zeitschrift Science Advances
Quellenangaben Band: 10, Heft: 10, Seiten: , Artikelnummer: eadl1122 Supplement: ,
Verlag American Association for the Advancement of Science (AAAS)
Verlagsort Washington, DC [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research (IDF)
Institute of Pancreatic Islet Research (IPI)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502190-001
G-502600-001
Förderungen Leona M. & Harry B. Helmsley Charitable Trust
Swedish Research Council
Swedish Child Diabetes Foundation
Strategic Research Program in Diabetes at Karolinska Institutet
Federal Ministry for Education and Research (BMBF)
National Institutes of Health NIDDK grant
Steve Morgan Foundation Grand Challenge Senior Research Fellowship
Novo Nordisk Postdoctoral Fellowship program at Karolinska Institutet
JDRF Postdoctoral Fellowship
Agence Nationale de la Recherche grant
Fondation pour la Recherche Medicale grant
JDRF
Human Atlas of Neonatal Development and Early Life Immunity program (HANDEL-I)
European Federation of Pharmaceutical Industries and Associations
EU
Innovative Medicines Initiative 2 Joint Undertaking
JDRF nPOD-Virus grant
DOI 10.1126/sciadv.adl1122
WOS ID 001187009700006
Scopus ID 85187208740
PubMed ID 38446892
Erfassungsdatum 2024-05-03
[➜Korrektur melden]